{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:21:12Z","timestamp":1792614072021,"version":"4.5.0"},"reference-count":85,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"9","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2026,3,20]]},"abstract":"\n ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the<\/jats:italic>\n \n ASCO Guidelines Methodology Manual<\/jats:italic>\n <\/jats:ext-link>\n . ASCO Guidelines follow the<\/jats:italic>\n \n ASCO Conflict of Interest Policy for Clinical Practice Guidelines<\/jats:italic>\n <\/jats:ext-link>\n .\n <\/jats:p>\n \n \n Clinical Practice Guidelines and other guidance (\u201cGuidance\u201d) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in\n Appendix 1<\/jats:xref>\n and\n Appendix 2<\/jats:xref>\n (online only) for more\n <\/jats:italic>\n .\n <\/jats:p>\n \n PURPOSE<\/jats:title>\n To update the ASCO guideline on use of hematopoietic colony-stimulating factors (CSFs) in patients with cancer.<\/jats:p>\n <\/jats:sec>\n \n METHODS<\/jats:title>\n A systematic review identified randomized controlled trials (RCTs), meta-analyses, and systematic reviews that addressed use of CSFs for the prevention or treatment of neutropenic events, or for mobilization of stem cells, in adults with cancer. PubMed and the Cochrane Library were searched for articles published from September 1, 2014, to August 22, 2025. ASCO convened an Expert Panel to review the evidence and formulate recommendations.<\/jats:p>\n <\/jats:sec>\n \n RESULTS<\/jats:title>\n The updated systematic review included 33 RCTs and 16 systematic reviews. Additions to the body of evidence include approval of new CSFs and additional biosimilars, and approval of an additional CXCR4 inhibitor that may be used with CSFs for the mobilization of hematopoietic stem cells.<\/jats:p>\n <\/jats:sec>\n \n RECOMMENDATIONS<\/jats:title>\n Prophylactic use of CSFs to reduce the risk of febrile neutropenia is warranted when the risk of febrile neutropenia from chemotherapy is approximately 20% or higher and no other equally effective and safe regimen that does not require CSFs is available. For patients receiving chemotherapy with a <20% risk of febrile neutropenia, primary prophylaxis with a CSF may be warranted if patients are at a high risk of febrile neutropenia based on age, medical history, or disease characteristics. For stem-cell mobilization, CSFs may be used either alone, after chemotherapy, or in combination with plerixafor or motixafortide. The guideline also provides information about the dosing and selection of CSFs.<\/jats:p>\n \n Additional information is available at\n www.asco.org\/supportive-care-guidelines<\/jats:ext-link>\n .\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1200\/jco-25-02938","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T20:59:06Z","timestamp":1772053146000},"page":"812-824","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":16,"title":["WBC Growth Factors: ASCO Guideline Update"],"prefix":"10.1200","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7444-8594","authenticated-orcid":false,"given":"Bishal","family":"Gyawali","sequence":"first","affiliation":[{"name":"Queen's University, Kingston, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1529-7903","authenticated-orcid":false,"given":"Kari","family":"Bohlke","sequence":"additional","affiliation":[{"name":"American Society of Clinical Oncology, Alexandria, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5579-1573","authenticated-orcid":false,"given":"Jana K.","family":"Dickter","sequence":"additional","affiliation":[{"name":"City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7627-8509","authenticated-orcid":false,"given":"Amar H.","family":"Kelkar","sequence":"additional","affiliation":[{"name":"Dana Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin B.","family":"Knopf","sequence":"additional","affiliation":[{"name":"Highland Hospital, Alameda Health System, Oakland, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7610-3653","authenticated-orcid":false,"given":"Bernardo L.","family":"Rapoport","sequence":"additional","affiliation":[{"name":"The Medical Oncology Centre of Rosebank, Johannesburg, South Africa"},{"name":"Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9362-7851","authenticated-orcid":false,"given":"Logan","family":"Roof","sequence":"additional","affiliation":[{"name":"The Ohio State University Wexner Medical Center, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Schott","sequence":"additional","affiliation":[{"name":"Patient Advocate, Medford, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5106-1979","authenticated-orcid":false,"given":"Madhav R.","family":"Seshadri","sequence":"additional","affiliation":[{"name":"University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8594-6975","authenticated-orcid":false,"given":"Ramila","family":"Shilpakar","sequence":"additional","affiliation":[{"name":"Bir Hospital, National Academy of Medical Sciences, Kathmandu, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3040-6434","authenticated-orcid":false,"given":"Thomas J.","family":"Smith","sequence":"additional","affiliation":[{"name":"Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1672-9560","authenticated-orcid":false,"given":"Dario","family":"Trapani","sequence":"additional","affiliation":[{"name":"University of Milan, European Institute of Oncology, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy B.","family":"Woodard","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Cigler","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_9_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac074"},{"key":"e_1_3_9_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6211"},{"key":"e_1_3_9_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct1210890"},{"key":"e_1_3_9_5_2","volume-title":"NCCN Guidelines Version 1.2025 Hematopoietic Growth Factors","author":"National Comprehensive Cancer Network","year":"2024","unstructured":"National Comprehensive Cancer Network: NCCN Guidelines Version 1.2025 Hematopoietic Growth Factors (ed 01.2025), 2024. https:\/\/www.nccn.org"},{"key":"e_1_3_9_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3488"},{"key":"e_1_3_9_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01435"},{"key":"e_1_3_9_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604"},{"key":"e_1_3_9_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.07.015"},{"key":"e_1_3_9_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx638"},{"key":"e_1_3_9_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13358"},{"key":"e_1_3_9_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-04773-6"},{"key":"e_1_3_9_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2021.03.012"},{"key":"e_1_3_9_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.04.005"},{"key":"e_1_3_9_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3227"},{"key":"e_1_3_9_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0798-6"},{"key":"e_1_3_9_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02273-z"},{"key":"e_1_3_9_18_2","first-page":"4049","article-title":"Long-acting granulocyte colony-stimulating factor in primary prophylaxis of early infection in patients with newly diagnosed multiple myeloma","volume":"30","author":"Ding X","year":"2022","unstructured":"Ding X, Ding J, Gu H, et al: Long-acting granulocyte colony-stimulating factor in primary prophylaxis of early infection in patients with newly diagnosed multiple myeloma. Support Care Cancer 30:4049-4054, 2022","journal-title":"Support Care Cancer"},{"key":"e_1_3_9_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-015-3531-z"},{"key":"e_1_3_9_20_2","article-title":"Primary febrile neutropenia prophylaxis for patients who receive FEC-D chemotherapy for breast cancer: A systematic review","author":"Fernandes R","unstructured":"Fernandes R, Mazzarello S, Stober C, et al: Primary febrile neutropenia prophylaxis for patients who receive FEC-D chemotherapy for breast cancer: A systematic review. JCO Glob Oncol 10.1200\/JGO.2016.008540","journal-title":"JCO Glob Oncol"},{"key":"e_1_3_9_21_2","first-page":"34","article-title":"Efbemalenograstim alfa, an Fc fusion protein, long-acting granulocyte-colony stimulating factor for reducing the risk of febrile neutropenia following chemotherapy: Results of a phase III trial","volume":"32","author":"Glaspy J","year":"2023","unstructured":"Glaspy J, Bondarenko I, Burdaeva O, et al: Efbemalenograstim alfa, an Fc fusion protein, long-acting granulocyte-colony stimulating factor for reducing the risk of febrile neutropenia following chemotherapy: Results of a phase III trial. Support Care Cancer 32:34, 2023","journal-title":"Support Care Cancer"},{"key":"e_1_3_9_22_2","first-page":"91","article-title":"Efbemalenograstim alfa not inferior to pegfilgrastim in providing neutrophil support in women with breast cancer undergoing myelotoxic chemotherapy: Results of a phase 2 randomized, multicenter, open-label trial","volume":"32","author":"Glaspy J","year":"2024","unstructured":"Glaspy J, Bondarenko I, Krasnozhon D, et al: Efbemalenograstim alfa not inferior to pegfilgrastim in providing neutrophil support in women with breast cancer undergoing myelotoxic chemotherapy: Results of a phase 2 randomized, multicenter, open-label trial. Support Care Cancer 32:91, 2024","journal-title":"Support Care Cancer"},{"key":"e_1_3_9_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-98453-7"},{"key":"e_1_3_9_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.09.012"},{"key":"e_1_3_9_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01258"},{"key":"e_1_3_9_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2021.100454"},{"key":"e_1_3_9_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15507"},{"key":"e_1_3_9_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-024-02468-z"},{"key":"e_1_3_9_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14233"},{"key":"e_1_3_9_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.14165"},{"key":"e_1_3_9_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-017-3959-2"},{"key":"e_1_3_9_32_2","article-title":"Biosimilar versus originator pegfilgrastim for preventing chemotherapy-induced neutropenia: A phase III randomized, multicenter, evaluator-blinded, noninferiority study","author":"Kowalyszyn RD","unstructured":"Kowalyszyn RD, Fein LE, Richardet ME, et al: Biosimilar versus originator pegfilgrastim for preventing chemotherapy-induced neutropenia: A phase III randomized, multicenter, evaluator-blinded, noninferiority study. JCO Glob Oncol 10.1200\/GO.21.00276","journal-title":"JCO Glob Oncol"},{"key":"e_1_3_9_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103193"},{"key":"e_1_3_9_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv389"},{"key":"e_1_3_9_35_2","doi-asserted-by":"publisher","DOI":"10.17305\/bjbms.2022.7859"},{"key":"e_1_3_9_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05603-w"},{"key":"e_1_3_9_37_2","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2329140"},{"key":"e_1_3_9_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05711-7"},{"key":"e_1_3_9_39_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-022-02802-6"},{"key":"e_1_3_9_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy311"},{"key":"e_1_3_9_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2654-4"},{"key":"e_1_3_9_42_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-023-00576-8"},{"key":"e_1_3_9_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2016.08.008"},{"key":"e_1_3_9_44_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0105"},{"key":"e_1_3_9_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14544"},{"key":"e_1_3_9_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv619"},{"key":"e_1_3_9_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-021-06387-1"},{"key":"e_1_3_9_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03639-5"},{"key":"e_1_3_9_49_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.5121"},{"key":"e_1_3_9_50_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000028218"},{"key":"e_1_3_9_51_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04376-w"},{"key":"e_1_3_9_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-51982-4"},{"key":"e_1_3_9_53_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-13156-y"},{"key":"e_1_3_9_54_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-019-00356-3"},{"key":"e_1_3_9_55_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0315001"},{"key":"e_1_3_9_56_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.16151"},{"key":"e_1_3_9_57_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12892-5"},{"key":"e_1_3_9_58_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08364-9"},{"key":"e_1_3_9_59_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00374"},{"key":"e_1_3_9_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2013.12.006"},{"key":"e_1_3_9_61_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2597-1"},{"key":"e_1_3_9_62_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.8364"},{"key":"e_1_3_9_63_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199107183250305"},{"key":"e_1_3_9_64_2","doi-asserted-by":"publisher","DOI":"10.3816\/SCT.2005.n.023"},{"key":"e_1_3_9_65_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199706193362502"},{"key":"e_1_3_9_66_2","first-page":"Cd003039","article-title":"Colony-stimulating factors for chemotherapy-induced febrile neutropenia","volume":"2014","author":"Mhaskar R","year":"2014","unstructured":"Mhaskar R, Clark OA, Lyman G, et al: Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev 2014:Cd003039, 2014","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_9_67_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.1663"},{"key":"e_1_3_9_68_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704108"},{"key":"e_1_3_9_69_2","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181f585c7"},{"key":"e_1_3_9_70_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.06.102"},{"key":"e_1_3_9_71_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.7.1632"},{"key":"e_1_3_9_72_2","first-page":"75","article-title":"Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial","volume":"74","author":"Sheikh H","year":"2011","unstructured":"Sheikh H, Colaco R, Lorigan P, et al: Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial. Lung Cancer 74:75-79, 2011","journal-title":"Lung Cancer"},{"key":"e_1_3_9_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.01.025"},{"key":"e_1_3_9_74_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00783"},{"key":"e_1_3_9_75_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.091094"},{"key":"e_1_3_9_76_2","volume-title":"Timing of Pegfilgrastim Administration and Pegfilgrastim-Induced Bone Pain: A Prospective, Randomized Phase 3 Trial. Abstract 297MO. Presented at the ESMO Congress 2025","author":"Wang K","year":"2025","unstructured":"Wang K, Li P, Yang C, et al: Timing of Pegfilgrastim Administration and Pegfilgrastim-Induced Bone Pain: A Prospective, Randomized Phase 3 Trial. Abstract 297MO. Presented at the ESMO Congress 2025, Berlin, Germany, 2025"},{"key":"e_1_3_9_77_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.21.00148"},{"key":"e_1_3_9_78_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.2311"},{"key":"e_1_3_9_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100269"},{"key":"e_1_3_9_80_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.24.00339"},{"key":"e_1_3_9_81_2","first-page":"581","article-title":"Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer","volume":"31","author":"Aapro MS","year":"2023","unstructured":"Aapro MS, Chaplin S, Cornes P, et al: Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer. Support Care Cancer 31:581, 2023","journal-title":"Support Care Cancer"},{"key":"e_1_3_9_82_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0303294"},{"key":"e_1_3_9_83_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024027053"},{"key":"e_1_3_9_84_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.1183"},{"key":"e_1_3_9_85_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00542"},{"key":"e_1_3_9_86_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00933"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-25-02938","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T22:00:29Z","timestamp":1773784829000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-02938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":85,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,3,20]]}},"alternative-id":["10.1200\/JCO-25-02938"],"URL":"https:\/\/doi.org\/10.1200\/jco-25-02938","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1200\/GDL.26.0225","asserted-by":"subject"}]},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"2025-12-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}